Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.

Fleming, G F; Pagani, O; Regan, M M; Walley, B A; Francis, P A

Fleming, G F; Pagani, O; Regan, M M; Walley, B A; Francis, P A.

Afiliación

Fleming GF; Department of Medicine, The University of Chicago Medical Center, Chicago, USA. Electronic address: gfleming@medicine.bsd.uchicago.edu.
Pagani O; Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), Vaud, Switzerland.
Regan MM; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, USA.
Walley BA; University of Calgary and Canadian Cancer Trials Group, Calgary, Canada.
Francis PA; Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Australia.

Ann Oncol ; 33(6): 658, 2022 06.

Article en En | MEDLINE | ID: mdl-35301096

Asunto(s)

Neoplasias de la Mama; Aminopiridinas; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos; Bencimidazoles/uso terapéutico; Neoplasias de la Mama/tratamiento farmacológico; Femenino; Humanos; Antígeno Ki-67; Receptor ErbB-2

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google